Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues

Mengsha Tong; Weicheng Zheng; Xingrong Lu; Lu Ao; Xiangyu Li; Qingzhou Guan; Hao Cai; Mengyao Li; Haidan Yan; You Guo; Pan Chi; Zheng Guo

doi:10.18632/oncotarget.5649

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues

Mengsha Tong, Weicheng Zheng, Xingrong Lu, Lu Ao, Xiangyu Li, Qingzhou Guan, Hao Cai, Mengyao Li, Haidan Yan, You Guo, Pan Chi and Zheng Guo _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:41216-41227. https://doi.org/10.18632/oncotarget.5649

Metrics: PDF 1741 views | HTML 2266 views | ?

Abstract

Mengsha Tong1, Weicheng Zheng1, Xingrong Lu2, Lu Ao1, Xiangyu Li1, Qingzhou Guan1, Hao Cai1, Mengyao Li1, Haidan Yan1, You Guo1, Pan Chi2, Zheng Guo1

1Department of Bioinformatics, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China

2Department of Colorectal & Anal Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China

Correspondence to:

Zheng Guo, e-mail: [email protected]

Pan Chi, e-mail: [email protected]

Keywords: drug-induced resistant cancer cell lines, drug treatment response, colorectal cancer, 5-fluorouracil, oxaliplatin

Received: June 30, 2015 Accepted: September 12, 2015 Published: October 15, 2015

ABSTRACT

Until recently, few molecular signatures of drug resistance identified in drug-induced resistant cancer cell models can be translated into clinical practice. Here, we defined differentially expressed genes (DEGs) between pre-chemotherapy colorectal cancer (CRC) tissue samples of non-responders and responders for 5-fluorouracil and oxaliplatin-based therapy as clinically relevant drug resistance genes (CRG_5-FU/L-OHP). Taking CRG_5-FU/L-OHP as reference, we evaluated the clinical relevance of several types of genes derived from HCT116 CRC cells with resistance to 5-fluorouracil and oxaliplatin, respectively. The results revealed that DEGs between parental and resistant cells, when both were treated with the corresponding drug for a certain time, were significantly consistent with the CRG_5-FU/L-OHP as well as the DEGs between the post-chemotherapy CRC specimens of responders and non-responders. This study suggests a novel strategy to extract clinically relevant drug resistance genes from both drug-induced resistant cell models and post-chemotherapy cancer tissue specimens.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5649

Publication Alerts

Research Papers:

Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues

Abstract